{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:23:58Z","timestamp":1784910238339,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01798","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T04:19:11Z","timestamp":1533269951000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model"],"prefix":"10.3389","volume":"9","author":[{"given":"Manh-Cuong","family":"Vo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan-Huy","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thangaraj Jaya","family":"Lakshmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Seong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeoung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.critrevonc.2017.01.011","article-title":"Immunotherapy for the treatment of multiple myeloma","volume":"111","author":"Jung","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.3109\/10428194.2014.905775","article-title":"Risk adapted therapy for multiple myeloma: back to basics","volume":"55","author":"Kumar","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1046\/j.1365-2141.2001.02626.x","article-title":"Dendritic cells and immunotherapy for malignant disease","volume":"112","author":"Reid","year":"2001","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4068\/cmj.2015.51.1.1","article-title":"Dendritic cell-based cancer immunotherapy against multiple myeloma: from bench to clinic","volume":"51","author":"Hoang","year":"2015","journal-title":"Chonnam Med J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.jcyt.2015.06.002","article-title":"Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco\/endoplasmic reticulum Ca(2+) transport ATPase 2 regulation","volume":"17","author":"Choi","year":"2015","journal-title":"Cytotherapy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"706379","DOI":"10.1155\/2015\/706379","article-title":"Branched polyethylenimine-superparamagnetic iron oxide nanoparticles (bPEI-SPIONs) improve the immunogenicity of tumor antigens and enhance Th1 polarization of dendritic cells","volume":"2015","author":"Hoang","year":"2015","journal-title":"J Immunol Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1038\/emm.2016.69","article-title":"Sarcoplasmic reticulum Ca(2+) ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells","volume":"48","author":"Hong","year":"2016","journal-title":"Exp Mol Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.exphem.2013.12.008","article-title":"Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro","volume":"42","author":"Jung","year":"2014","journal-title":"Exp Hematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-4939-0345-0_2","article-title":"Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine","volume":"1139","author":"Lee","year":"2014","journal-title":"Methods Mol Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"46047","DOI":"10.18632\/oncotarget.17517","article-title":"Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells","volume":"8","author":"Vo","year":"2017","journal-title":"Oncotarget"},{"key":"B14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3858\/emm.2010.42.6.042","article-title":"Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of toll-like receptor agonist","volume":"42","author":"Pham","year":"2010","journal-title":"Exp Mol Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"33781","DOI":"10.18632\/oncotarget.5281","article-title":"Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity","volume":"6","author":"Vo","year":"2015","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/CJI.0000000000000097","article-title":"Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma","volume":"38","author":"Nguyen-Pham","year":"2015","journal-title":"J Immunother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"41538","DOI":"10.18632\/oncotarget.14582","article-title":"A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma","volume":"8","author":"Jung","year":"2017","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1038\/bcj.2013.38","article-title":"Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma","volume":"3","author":"Chanan-Khan","year":"2013","journal-title":"Blood Cancer J"},{"key":"B19","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1182\/blood-2010-10-314278","article-title":"IMiD immunomodulatory compounds block C\/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.leukres.2014.02.008","article-title":"Preclinical and clinical results with pomalidomide in the treatment of relapsed\/refractory multiple myeloma","volume":"38","author":"Mark","year":"2014","journal-title":"Leuk Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"s36","DOI":"10.1016\/j.critrevonc.2013.02.001","article-title":"Pomalidomide: new immunomodulatory agent with potent antiproliferative effects","volume":"88","author":"Richardson","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.immuni.2007.03.014","article-title":"T cell-produced transforming growth factor-\u03b21 controls T cell tolerance and regulates Th1- and Th17-cell differentiation","volume":"26","author":"Li","year":"2007","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","article-title":"Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma","volume":"116","author":"Gorgun","year":"2010","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/blood.V114.22.4926.4926","article-title":"The anti-proliferative effect of lenalidomide on MM cells in vitro is ameliorated by prior exposure to pomalidomide, an agent with activity against lenalidomide resistant MM cells","volume":"114","author":"Mary Adams","year":"2009","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/bjh.13905","article-title":"Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma","volume":"172","author":"Rychak","year":"2016","journal-title":"Br J Haematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7347","DOI":"10.1158\/0008-5472.CAN-08-4898","article-title":"Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism","volume":"69","author":"Escoubet-Lozach","year":"2009","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1182\/blood-2012-08-450742","article-title":"Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib","volume":"121","author":"Richardson","year":"2013","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"27252","DOI":"10.18632\/oncotarget.15917","article-title":"Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model","volume":"8","author":"Vo","year":"2017","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3389\/fimmu.2018.01370","article-title":"Lenalidomide and programmed death-1 blockade synergistically enhances the effects of dendritic cell vaccination in a model of murine myeloma","volume":"9","author":"Vo","year":"2018","journal-title":"Front Immunol"},{"key":"B36","first-page":"B4171","article-title":"Dendritic cell vaccination of patients with metastatic colorectal cancer","volume":"57","author":"Burgdorf","year":"2010","journal-title":"Dan Med Bull"},{"key":"B37","doi-asserted-by":"publisher","first-page":"183602","DOI":"10.1155\/2013\/183602","article-title":"Multiple myeloma macrophages: pivotal players in the tumor microenvironment","volume":"2013","author":"Berardi","year":"2013","journal-title":"J Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fimmu.2015.00091","article-title":"Dendritic cell-based vaccine efficacy: aiming for hot spots","volume":"6","author":"Pizzurro","year":"2015","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.exphem.2016.11.004","article-title":"Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma","volume":"46","author":"Vo","year":"2017","journal-title":"Exp Hematol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/bonekey.2015.142","article-title":"Preclinical animal models of multiple myeloma","volume":"5","author":"Lwin","year":"2016","journal-title":"Bonekey Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"814","DOI":"10.2174\/156800912802429292","article-title":"Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma","volume":"12","author":"Tassone","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0471141755.ph1409s40","article-title":"Animal models of multiple myeloma and their utility in drug discovery","volume":"40","author":"Richard","year":"2008","journal-title":"Curr Protoc Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01798\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T04:12:17Z","timestamp":1693800737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01798\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,3]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2018.01798"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01798","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,3]]},"article-number":"1798"}}